Skip to main content

Table 3 Response to treatment

From: Continuous 5-fluorouracil infusion plus long acting octreotide in advanced well-differentiated neuroendocrine carcinomas. A phase II trial of the Piemonte Oncology Network

  Clinical response
(RECIST)
N = 29
No. (%)
Biochemical response (Chromogranin A)
N = 25
No. (%)
Symptomatic response
N = 15
No. (%)
Progression 2 (6.9) 2 (8.0)  
No change 20 (69.0) 11 (44.0) 6 (40.0)
Partial response 7 (24.1) 8 (32.0) 6 (40.0)
Complete response - 4 (16.0) 3 (20.0)
Overall response 7 (24.1)
(95% CI 8.3-39.9)
12 (48.0)
(95% CI 28.0-68.0)
9 (60.0)
  1. RECIST = Response Evaluation Criteria in Solid Tumors